meta_pixel
Tapesearch Logo
Log in
Marketplace All-in-One

What’s going on at the FDIC?

Marketplace All-in-One

Marketplace

News, Business

4.51.4K Ratings

🗓️ 23 November 2023

⏱️ 8 minutes

🧾️ Download transcript

Summary

The chair of the FDIC was grilled during Congressional hearings last week following reports by the Wall Street Journal on allegations of sexual harassment and racial discrimination at the agency. We’ll dig into the responses to and potential consequences of the alleged toxic culture. Plus, we hear what’s being discussed in earnings calls and learn how Ukrainian women are stepping up to fill traditionally male industries.

Transcript

Click on a timestamp to play from that location

0:00.0

Best Internal

0:03.2

temperature for Roasting a turkey 165 degrees Fahrenheit that taken care of we're gonna look at corporate profits here

0:11.4

I'm David Brancaccio on a Thanksgiving morning. Let's catch up now on a key

0:16.2

engine of the economy profits at companies. So far firms on the S&P 500 list have

0:22.1

reported that profits have grown about 4% on average in the quarter

0:26.0

gone by.

0:27.0

That striking, given all the expert predictions, the U.S. would be in recession by now?

0:31.3

We are not.

0:32.3

Something else notable in this cascade of

0:34.4

profit and losses is what analysts were looking for when they questioned

0:38.4

company leaders about the road ahead. Marketplaces Novosafo has that.

0:42.4

It seems obvious that if you're a drug and GLP1 drugs, then you'd expect analysts, which are tasked with forecasting future performance,

0:55.8

to ask you about those drugs.

0:57.9

But in recent calls with analysts, company leaders in other sectors fielded questions about

1:02.0

the drugs as well,

1:03.5

such as Pepsico CEO Ramon LaGuarda.

1:06.3

So far, the impact is negligible in our business.

1:09.3

There's obviously a lot of question marks

1:11.7

with regards to these obesity drugs and Hershey

1:14.9

CEO Michelle Buck certainly there are opportunities around portion size and

1:19.5

pack type and I think a lot of companies have been focused on that as you think about the potential impact of GLP1.

1:26.0

Medical device companies were quizzed about potentially fewer procedures, health insurers about higher costs if they have to pay for expensive prescriptions.

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from Marketplace, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Marketplace and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2026.